PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum

Cell Death and Differentiation

Volumn 17, Issue 2, 2010, Pages 324-335

  Saavedra, A ^a,b   Garcia Martinez J M ^a,b,d   Xifro X ^a,b   Giralt, A ^a,b   Torres Peraza, J F ^a,b,e   Canals, J M ^a,b   Diaz Hernandez M ^b,c   Lucas, J J ^b,c   Alberch, J ^a,b   Perez Navarro E ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

E xcitotoxicity; Exon 1 mouse models; FoxO1; GSK3 ; Human samples; Huntingtin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; MUTANT PROTEIN; PH DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 1; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PUTAMEN; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANIMALS; CELL DEATH; CELL LINE, TRANSFORMED; CELL NUCLEUS; CORPUS STRIATUM; CYTOSOL; DISEASE MODELS, ANIMAL; EXONS; FEMALE; GENE KNOCK-IN TECHNIQUES; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEUROTOXINS; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT;

MUS; MUS MUSCULUS;

EID: 74249105655     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.127     Document Type: Article

References (47)

1. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986; 315: 1267-1276.
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
3. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993; 5: 259-265.
4. de la Monte SM, Vonsattel JP, Richardson Jr EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988; 47: 516-525.
5. Perez-Navarro E, Canals JM, Gines S, Alberch J. Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. Histol Histopathol 2006; 21: 1217-1232.
6. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
7. Owada Y, Utsunomiya A, Yoshimoto T, Kondo H. Expression of mRNA for Akt, serine-threonine protein kinase, in the brain during development and its transient enhancement following axotomy of hypoglossal nerve. J Mol Neurosci 1997; 9: 27-33.
8. Chong ZZ, Li F, Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 2005; 20: 299-315.
9. Noshita N, Lewen A, Sugawara T, Chan PH. Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2001; 21: 1442-1450.
10. Endo H, Nito C, Kamada H, Nishi T, Chan PH. Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 2006; 26: 1479-1489.
11. Zhang X, Chen Y, Ikonomovic MD, Nathaniel PD, Kochanek PM, Marion DW et al. Increased phosphorylation of protein kinase B and related substrates after traumatic brain injury in humans and rats. J Cereb Blood Flow Metab 2006; 26: 915-926.
12. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 2003; 278: 50514-50522.
13. Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, Crews L et al. Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J Biol Chem 2004; 279: 23622-23629.
14. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002; 2: 831-837.
15. Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 2005; 18: 143-145.
16. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-6551.
17. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18: 13-24.
18. Hill MM, Andjelkovic M, Brazil DP, Ferrari S, Fabbro D, Hemmings BA. Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem 2001; 276: 25643-25646.
19. Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem 2008; 283: 6300-6311.
20. Shimizu K, Okada M, Takano A, Nagai K. SCOP, a novel gene product expressed in a circadian manner in rat suprachiasmatic nucleus. FEBS Lett 1999; 458: 363-369.
21. Shimizu K, Phan T, Mansuy IM, Storm DR. Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. Cell 2007; 128: 1219-1229.
22. Jackson TC, Rani A, Kumar A, Foster TC. Regional hippocampal differences in AKT survival signaling across the lifespan: implications for CA1 vulnerability with aging. Cell Death Differ 2009; 16: 439-448.
23. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007; 24: 7727-7739.
24. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 2004; 24: 7727-7739.
25. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem 1997; 272: 30491-30497. (Pubitemid 27512261)
26. van der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; 380: 297-309.
27. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 1999; 96: 8727-8732.
28. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004; 20: 146-154.
29. Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H et al. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J 2008; 27: 827-839.
30. Xu J, Zhang QG, Li C, Zhang GY. Subtoxic N-methyl-D-aspartate delayed neuronal death in ischemic brain injury through TrkB receptor-and calmodulin-mediated PI-3K/Akt pathway activation. Hippocampus 2007; 17: 525-537.
31. Wang X, McCullough KD, Franke TF, Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 2000; 275: 14624-14631.
32. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007; 81: 272-293.
33. Klepac N, Relja M, Klepac R, Hecimovic S, Babic T, Trkulja V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 2007; 254: 1676-1683.
34. Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004; 127: 505-516.
35. Kaytor MD, Byam CE, Tousey SK, Stevens SD, Zoghbi HY, Orr HT. A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet 2005; 14: 1095-1105.
36. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 2005; 14: 1569-1577.
37. Lievens JC, Iche M, Laval M, Faivre-Sarrailh C, Birman S. AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease. Hum Mol Genet 2008; 17: 882-894.
38. Branco J, Al Ramahi I, Ukani L, Perez AM, Fernandez-Funez P, Rincon-Limas D et al. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum Mol Genet 2008; 17: 376-390.
39. Colin E, Regulier E, Perrin V, Durr A, Brice A, Aebischer P et al. Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 2005; 21: 1478-1488.
40. Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S et al. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem 2003; 87: 1184-1192.
41. Garcia-Martinez JM, Perez-Navarro E, Xifro X, Canals JM, Diaz-Hernandez M, Trioulier Y et al. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. J Neurosci Res 2007; 85: 2756-2769.
42. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
43. Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J, Lucas JJ. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 2001; 21: 8772-8781.
44. Diaz-Hernandez M, Torres-Peraza J, Salvatori-Abarca A, Moran MA, Gomez-Ramos P, Alberch J et al. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci 2005; 25: 9773-9781.
45. Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 1999; 8: 115-122.
46. Ernfors P, Lee KF, Jaenisch R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 1994; 368: 147-150.
47. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101: 57-66.